| 商品名称 | Exdensur |
|---|---|
| 适用类别 | Human |
| 治疗领域 | Asthma;Nasal Polyps |
| 通用名/非专利名称 | depemokimab |
| 活性成分 | depemokimab |
| 产品号 | EMEA/H/C/006446 |
| 患者安全信息 | No |
| 许可状态 | Authorised |
| ATC编码 | R03DX12 |
| 是否额外监管 | Yes |
| 是否仿制药或hybrid药物 | No |
| 是否生物类似药 | No |
| 是否附条件批准 | No |
| 是否特殊情形 | No |
| 是否加速审评 | No |
| 是否罕用药 | No |
| 上市许可日期 | 2026/02/12 |
| 上市许可开发者/申请人/持有人 | GlaxoSmithKline Trading Services Limited |
| 人用药物治疗学分组 | Drugs for obstructive airway diseases |
| 兽用药物治疗学分组 | |
| 审评意见日期 | 2025/12/11 |
| 修订号 | |
| 治疗适应症 | Asthma Exdensur is indicated as add-on maintenance treatment for severe asthma with type 2 inflammation characterised by blood eosinophil count in adults and adolescents 12 years and older who are inadequately controlled despite high dose inhaled corticosteroids (ICS) plus another asthma controller (see section 5.1). Chronic rhinosinusitis with nasal polyps (CRSwNP) Exdensur is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adult patients with severe CRSwNP for whom therapy with systemic corticosteroids and/or surgery do not provide adequate disease control. |
| 适用物种 | |
| 兽用药物ATC编码 | |
| 首次发布日期 | 2025/12/12 |
| 最后更新日期 | 2026/03/12 |
| 产品说明书 | https://www.ema.europa.eu/en/documents/product-information/exdensur-epar-product-information_en.pdf |
| 公共评估报告 | https://www.ema.europa.eu/en/medicines/human/EPAR/exdensur |